Cannabidiol has been found to act as an antagonist of GPR55, a G protein-coupled receptor and putative cannabinoid receptor that is expressed in the caudate nucleus and putamen in the brain. It has also been found to act as an inverse agonist of GPR3, GPR6, and GPR12. Although currently classified as orphan receptors, these receptors are most closely related phylogeneticaly to the cannabinoid receptors. In addition to orphan receptors, CBD has been shown to act as a serotonin 5-HT1A receptor partial agonist, and this action may be involved in its antidepressant, anxiolytic, and neuroprotective effects. It is an allosteric modulator of the μ- and δ-opioid receptors as well. The pharmacological effects of CBD have additionally been attributed to PPARγ agonism and intracellular calcium release.
Cannabis is believed to be an aggravating factor in rare cases of arteritis, a serious condition that in some cases leads to amputation. Because 97% of case-reports also smoked tobacco, a formal association with cannabis could not be made. If cannabis arteritis turns out to be a distinct clinical entity, it might be the consequence of vasoconstrictor activity observed from delta-8-THC and delta-9-THC. Other serious cardiovascular events including myocardial infarction, stroke, sudden cardiac death, and cardiomyopathy have been reported to be temporally associated with cannabis use. Research in these events is complicated because cannabis is often used in conjunction with tobacco, and drugs such as alcohol and cocaine. These putative effects can be taken in context of a wide range of cardiovascular phenomena regulated by the endocannabinoid system and an overall role of cannabis in causing decreased peripheral resistance and increased cardiac output, which potentially could pose a threat to those with cardiovascular disease. There is some evidence from case reports that cannabis use may provoke fatal cardiovascular events in young people who have not been diagnosed with cardiovascular disease. Smoking cannabis has also been shown to increase the risk of myocardial infarction by 4.8 times for the 60 minutes after consumption.
However, it is important to note that the production of derivatives or products made from whole industrial hemp plants, including sprouts, or the leaves, flowers or bracts of those plants, cannot be authorized by a licence issued under the IHR. Most activities with whole industrial hemp plants, including sprouts, or with the leaves, flowers or bracts of the plant, fall outside of the application of the IHR. These activities are controlled under the CDSA and are not authorized under the IHR."
Thanks for your interest in our products. Unfortunately due to strict FDA regulations I am unable to make claims on our products based on your specific needs, I can though share our top selling products in each category. Please view the links below:http://cbdoilreview.org/product/elixinol-cbd-oil-extract-x-pen-1000mg/http://cbdoilreview.org/product/endoca-hemp-oil-drops-1500mg/http://cbdoilreview.org/product/elixinol-hemp-oil-drops-regular-300mg/http://cbdoilreview.org/product/elixinol-cbd-hemp-oil-capsules-900mg/https://cbdoilreview.org/product/vape-bright-thrive-cbd-vape-cartridge-200mg/As far as dosage goes, I would recommend reading through our page on dosing. I have attached that link below. https://cbdoilreview.org/cbd-cannabidiol/cbd-dosage/Hopefully these help.
It’s a truism to state that pain is an inevitable part of life. And it’s true that we all, from time to time, experience pain that is short-lived and treatable. But those who deal with chronic pain know the debilitating, life-sucking reality of this condition. And traditional medications often come with long lists of side effects which can be as debilitating as the pain itself.
In addition, both plant-derived and endogenous cannabinoids have been studied for anti-inflammatory effects. A mouse study demonstrated that endogenous cannabinoid system signaling is likely to provide intrinsic protection against colonic inflammation. As a result, a hypothesis that phytocannabinoids and endocannabinoids may be useful in the risk reduction and treatment of colorectal cancer has been developed.[27-30]
A 2016 review of animal studies indicated that cannabidiol has potential as an anxiolytic for relief of anxiety-related disorders and fear. Reviews of preliminary research showed cannabidiol has potential for improving addictive disorders and drug dependence, although as of 2016, they indicated limited high-quality evidence for anti-addictive effects in people.
Hemp is a multi-purpose agricultural crop delivering seeds, fibers and bio-active chemicals for a number of uses and markets. Industrial hemp is defined in federal and Montana statute as Cannabis sativa L. that contains no more than 0.3% delta-9 tetrahydrocannabinol (THC). Industrial hemp is authorized as an alternative agricultural crop by the Montana Legislature, Section 80-18-101 through 80-18-111 of Montana Code Annotated.
The etymology is uncertain but there appears to be no common Proto-Indo-European source for the various forms of the word; the Greek term kánnabis is the oldest attested form, which may have been borrowed from an earlier Scythian or Thracian word. Then it appears to have been borrowed into Latin, and separately into Slavic and from there into Baltic, Finnish, and Germanic languages. Following Grimm's law, the "k" would have changed to "h" with the first Germanic sound shift, after which it may have been adapted into the Old English form, hænep. However, this theory assumes that hemp was not widely spread among different societies until after it was already being used as a psychoactive drug, which Adams and Mallory (1997) believe to be unlikely based on archaeological evidence. Barber (1991) however, argued that the spread of the name "kannabis" was due to its historically more recent drug use, starting from the south, around Iran, whereas non-THC varieties of hemp are older and prehistoric. Another possible source of origin is Assyrian qunnabu, which was the name for a source of oil, fiber, and medicine in the 1st millennium BC.